HAHeidi Sophia Maria Ammerlaan

Heidi Sophia Maria Ammerlaan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Heidi Sophia Maria Ammerlaan has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From losing control to regaining control: Patient experiences of care for Staphylococcus aureus bacteremia

    by Marianne M.C. Hendriks, Renée A.M. Tuinte, Anke J.M. Oerlemans, Heidi S.M. Ammerlaan, K. Slieker, Marlies E.J.L. Hulscher, Mihai G. Netea, Jaap Ten Oever, Ilse J.E. Kouijzer


  • Open Access

    Short-course aminoglycosides as adjunctive treatment in adults with sepsis: A post-hoc analysis of a prematurely terminated cluster randomized trial

    by Eva L. Koekenbier, Sharon E.J.D. van Den Eijnde, Paul D. van der Linden, Jan Jelrik Oosterheert, Elske Sieswerda, Lisanne E.M. Vintcent, Linda M. Kampschreur, Hjalmar R. Bouma, Heidi S.M. Ammerlaan, Michelle Gompelman, et al.


  • Observations of Communication Practices Between Men Who Have Sex With Men With HIV and HIV Specialist Nurses During Routine Consultations Regarding Sexual Health Counseling in the Netherlands: A Qualitative Study

    by Suzanne de Munnik, Chantal Den Daas, Heidi Sophia Maria Ammerlaan, Gerjo Kok, John de Wit, Sigrid Cornelia Johanna Maria Vervoort

    This study investigated how HIV specialist nurses communicate with men who have sex with men with HIV during routine consultations with a focus on sexual health counseling in the Netherlands. In this multicenter observational study, 16 video-recorded consultations from four HIV treatment centers were analyzed. Verbatim transcriptions were analyzed to assess the topics discussed, the duration of consultations, time spent on sexual health counseling, and specific issues covered. Communication skills were evaluated through a predefined framework. The findings indicated inconsistent coverage of sexual health, varied topics, and a lack of structure. Various communication skills and techniques were applied inconsistently. Given these findings, we recommend implementing communication strategies during routine consultations to improve the quality of sexual health counseling, especially for men who have sex with men with HIV. This is essential to improve the quality of sexual health counseling for persons with HIV, especially men who have sex with men.


  • Open Access

    Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen

    by Arjen J. Stam, Ninée V. E. J. Buchholtz, Wouter F. W. Bierman, Reinout van Crevel, Andy I. M. Hoepelman, Mark A. A. Claassen, Heidi S. M. Ammerlaan, Berend J. van Welzen, Marjo E. E. van Kasteren, Steven F. L. van Lelyveld, et al.

    There is an ongoing debate regarding whether low-level viremia (LLV), in particular persistent LLV, during HIV treatment with optimal adherence originates from low-level viral replication, viral production, or both. We performed an observational study in 30 individuals with LLV who switched to a boosted darunavir (DRV)-based therapy. In-depth virological analyses were used to characterize the viral population and the (activity) of the viral reservoir. Immune activation was examined using cell-bound and soluble markers. The primary outcome was defined as the effect on HIV-RNA and was categorized by responders (50 cp/mL). At week 24, 53% of the individuals were considered responders, 40% non-responders, and 7% could not be assigned. Sequencing showed no evolution or selection of drug resistance in the non-responders. Production of defective virus with mutations in either the protease (D25N) or RT active site contributed to persistent LLV in two individuals. We show that in about half of the study participants, the switch to a DRV-based regimen resulted in a viral response indicative of ongoing low-level viral replication as the cause of LLV before the switch. Our data confirm that in clinical management, high genetic barrier drugs like DRV are a safe choice, irrespective of the source of LLV.


  • Open Access

    Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study

    by Kathryn S. Hensley, Marlou J. Jongkees, Daryl Geers, Corine H. GeurtsvanKessel, Yvonne M. Mueller, Virgil A. S. H. Dalm, Grigorios Papageorgiou, Hanka Steggink, Alicja Gorska, Susanne Bogers, et al.

    Background: Vaccines can be less immunogenic in people living with HIV (PLWH), but for SARS-CoV-2 vaccinations this is unknown. In this study we set out to investigate, for the vaccines currently approved in the Netherlands, the immunogenicity and reactogenicity of SARS-CoV-2 vaccinations in PLWH. Methods and findings: We conducted a prospective cohort study to examine the immunogenicity of BNT162b2, mRNA-1273, ChAdOx1-S, and Ad26.COV2.S vaccines in adult PLWH without prior COVID-19, and compared to HIV-negative controls. The primary endpoint was the anti-spike SARS-CoV-2 IgG response after mRNA vaccination. Secondary endpoints included the serological response after vector vaccination, anti-SARS-CoV-2 T-cell response, and reactogenicity. Between 14 February and 7 September 2021, 1,154 PLWH (median age 53 [IQR 44–60] years, 85.5% male) and 440 controls (median age 43 [IQR 33–53] years, 28.6% male) were included in the final analysis. Of the PLWH, 884 received BNT162b2, 100 received mRNA-1273, 150 received ChAdOx1-S, and 20 received Ad26.COV2.S. In the group of PLWH, 99% were on antiretroviral therapy, 97.7% were virally suppressed, and the median CD4+ T-cell count was 710 cells/μL (IQR 520–913). Of the controls, 247 received mRNA-1273, 94 received BNT162b2, 26 received ChAdOx1-S, and 73 received Ad26.COV2.S. After mRNA vaccination, geometric mean antibody concentration was 1,418 BAU/mL in PLWH (95% CI 1322–1523), and after adjustment for age, sex, and vaccine type, HIV status remained associated with a decreased response (0.607, 95% CI 0.508–0.725, p < 0.001). All controls receiving an mRNA vaccine had an adequate response, defined as >300 BAU/mL, whilst in PLWH this response rate was 93.6%. In PLWH vaccinated with mRNA-based vaccines, higher antibody responses were predicted by CD4+ T-cell count 250–500 cells/μL (2.845, 95% CI 1.876–4.314, p < 0.001) or >500 cells/μL (2.936, 95% CI 1.961–4.394, p < 0.001), whilst a viral load > 50 copies/mL was associated with a reduced response (0.454, 95% CI 0.286–0.720, p = 0.001). Increased IFN-γ, CD4+ T-cell, and CD8+ T-cell responses were observed after stimulation with SARS-CoV-2 spike peptides in ELISpot and activation-induced marker assays, comparable to controls. Reactogenicity was generally mild, without vaccine-related serious adverse events. Due to the control of vaccine provision by the Dutch National Institute for Public Health and the Environment, there were some differences between vaccine groups in the age, sex, and CD4+ T-cell counts of recipients. Conclusions: After vaccination with BNT162b2 or mRNA-1273, anti-spike SARS-CoV-2 antibody levels were reduced in PLWH compared to HIV-negative controls. To reach and maintain the same serological responses as HIV-negative controls, additional vaccinations are probably required. Trial registration: The trial was registered in the Netherlands Trial Register (NL9214). https://www.trialregister.nl/trial/9214.


  • Open Access

    Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people living with HIV with hyporesponse after primary vaccination

    by Marlou J. Jongkees, Daryl Geers, Kathryn S. Hensley, Wesley Huisman, Corine H. GeurtsvanKessel, Susanne Bogers, Lennert Gommers, Grigorios Papageorgiou, Simon P. Jochems, Jan G. Den Hollander, et al.

    Background The COVIH study is a prospective SARS-CoV-2 vaccination study in people living with HIV (PLWH). Of the 1154 PLWH enrolled, 14% showed a reduced or absent antibody response after a primary vaccination regimen. As the response to an additional vaccination in PLWH with hyporesponse is unknown, we evaluated whether an additional vaccination boosts immune responses in these hyporesponders. Methods Consenting hyporesponders received an additional 100 µg of mRNA-1273. Hyporesponse was defined as ≤300 spike(S)-specific binding antibody units [BAU]/mL. The primary endpoint was the increase in antibodies 28 days after the additional vaccination. Secondary endpoints were the correlation between patient characteristics and antibody response, levels of neutralizing antibodies, S-specific T-cell and B-cell responses, and reactogenicity. Results Of the 75 PLWH enrolled, five were excluded as their antibody level had increased to >300 BAU/mL at baseline, two for a SARS-CoV-2 infection before the primary endpoint evaluation and two were lost to follow-up. Of the 66 remaining participants, 40 previously received ChAdOx1-S, 22 BNT162b2, and four Ad26.COV2.S. The median age was 63 [IQR:60-66], 86% were male, pre-vaccination and nadir CD4+ T-cell counts were 650/μL [IQR:423-941] and 230/μL [IQR:145-345] and 96% had HIV-RNA 300 BAU/mL in 64/66 (97%) with a mean increase of 4282 BAU/mL (95%CI:3241-5323). No patient characteristics correlated with the magnitude of the antibody response nor did the primary vaccination regimen. The additional vaccination significantly increased the proportion of participants with detectable ancestral S-specific B-cells (p=0.016) and CD4+ T-cells (p=0.037). Conclusion An additional mRNA-1273 vaccination induced a robust serological response in 97% of the PLWH with a hyporesponse after a primary vaccination regimen. This response was observed regardless of the primary vaccination regimen or patient characteristics.

  • Open Access

    A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study

    by Joachim Linssen, Anthony Ermens, Marvin Berrevoets, Michela Seghezzi, Giulia Previtali, Simone van der Sar-Van der Brugge, Henk Russcher, Annelies Verbon, Judith M.E.P. Gillis, Jürgen Riedl, et al.

    COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723-0.781) increasing to 0.875 (95% CI 0.806-0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients.